Esperion Therapeutics, Inc. (ESPR) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ESPR Revenue Growth
Revenue Breakdown (FY 2025)
ESPR's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
ESPR Revenue Analysis (2014–2025)
As of May 8, 2026, Esperion Therapeutics, Inc. (ESPR) generated trailing twelve-month (TTM) revenue of $403.1 million, reflecting explosive growth of +143.7% year-over-year. The most recent quarter (Q4 2025) recorded $168.4 million in revenue, up 92.9% sequentially.
Looking at the longer-term picture, ESPR's 5-year compound annual growth rate (CAGR) stands at +12.1%, indicating consistent double-digit revenue growth. The company achieved its highest annual revenue of $403.1 million in 2025, representing a new all-time high.
Revenue diversification analysis shows ESPR's business is primarily driven by Collaboration Revenue (60%), and Product (40%). With over half of revenue concentrated in Collaboration Revenue, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including MDGL (+256.8% YoY), PRTA (-58.0% YoY), and RARE (+13.3% YoY), ESPR has underperformed the peer group in terms of revenue growth. Compare ESPR vs MDGL →
ESPR Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ESPRCurrent | $403M | +143.7% | +12.1% | 15.0% | |
 MDGL | $958M | +256.8% | - | -31.3% | |
 PRTA | $10M | -58.0% | +62.6% | -1905.8% | |
 RARE | $673M | +13.3% | +19.9% | -79.5% | |
 ACAD | $1.1B | +9.9% | +19.4% | 9.8% |
ESPR Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $403.1M | +21.3% | $273.9M | 67.9% | $60.3M | 15.0% |
| 2024 | $332.3M | +185.7% | $263.7M | 79.4% | $54.4M | 16.4% |
| 2023 | $116.3M | +54.1% | $73.1M | 62.8% | $-155,563,000 | -133.7% |
| 2022 | $75.5M | -3.8% | $48.5M | 64.3% | $-179,501,000 | -237.8% |
| 2021 | $78.4M | -65.5% | $64.2M | 81.9% | $-226,730,000 | -289.0% |
| 2020 | $227.5M | +53.4% | $225.2M | 98.9% | $-121,396,000 | -53.3% |
| 2019 | $148.4M | -19.6% | $148.4M | 100.0% | $-93,101,000 | -62.8% |
| 2018 | $184.5M | - | $184.2M | 99.9% | $-204,585,000 | -110.9% |
| 2017 | $0 | - | $-258,000 | - | $-168,982,000 | - |
| 2016 | $0 | - | $-252,000 | - | $-76,150,000 | - |
See ESPR's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ESPR Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ESPR vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonESPR — Frequently Asked Questions
Quick answers to the most common questions about buying ESPR stock.
Is ESPR's revenue growth accelerating or slowing?
ESPR revenue is accelerating at +143.7% year-over-year, exceeding the 5-year CAGR of +12.1%. TTM revenue reached $403M. Growth momentum has increased versus prior periods.
What is ESPR's long-term revenue growth rate?
Esperion Therapeutics, Inc.'s 5-year revenue CAGR of +12.1% reflects the sustained expansion pattern. Current YoY growth of +143.7% is above this long-term average.
How is ESPR's revenue distributed by segment?
ESPR reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.